How to Help Your Patients Save Money on CellCept: A Provider's Guide to Savings Programs

Transplant recipients take CellCept (mycophenolate mofetil) for life — and medication costs are one of the leading factors in transplant medication non-adherence. For a drug that must never be skipped or stopped without physician guidance, medication cost is a direct patient safety issue.

This guide summarizes all available CellCept savings programs and prescribing strategies to help your patients manage costs without compromising their immunosuppression.

The Cost Problem: Why CellCept Is Expensive

Brand-name CellCept retails at approximately $886–$1,765 for 60–100 tablets, depending on strength. A heart transplant patient at 1.5 g BID could face retail costs exceeding $1,500/month for the brand product. Even generic mycophenolate mofetil can cost $100–$200/month at retail without assistance.

For patients on fixed incomes, Medicare, or with high-deductible commercial insurance, these costs can force choices between CellCept and other essential expenses. Transplant programs that routinely connect patients to available savings resources have lower rates of medication non-adherence.

Program 1: Genentech CellCept Co-Pay Card (Commercially Insured Patients)

The Genentech CellCept Co-Pay Card is available to commercially insured patients prescribed brand-name CellCept. Key features:

Reduces monthly co-pay to as little as $15 per fill

Maximum annual benefit: up to $10,000 in co-pay assistance

Eligible for patients with commercial (non-government) insurance only

Not valid for patients covered by Medicare, Medicaid, TRICARE, or VA

Program resets annually on January 1st; patients are auto-re-enrolled

Clinical implication: When generic MMF is unavailable or when you have a clinical reason to maintain brand CellCept for a patient, writing brand-name CellCept with the co-pay card enrolled means the patient's cost may actually be lower than their current generic copay. Have enrollment information available at your transplant clinic.

Program 2: Genentech Access to Care Foundation (Uninsured/Underinsured)

The Genentech Access to Care Foundation (GATCF) provides CellCept at no cost to patients who have no insurance or whose coverage has been denied. This is a critical safety net for transplant patients facing coverage gaps.

How to initiate an application:

Your practice completes the Genentech Access to Care Foundation Statement of Medical Necessity form.

The patient completes a Patient Authorization and Notice of Release of Information form and provides proof of income.

Both forms are submitted together. Contact GATCF at 1-888-754-7651 or via Genentech Access Solutions.

CellCept ships to the patient's home, your office, or a hospital/pharmacy of choice.

GATCF can also consider requests for off-label CellCept use, with a note in the application indicating that the use is for an off-label but medically indicated condition.

Program 3: PAN Foundation Patient Assistance

The Patient Advocate Network (PAN) Foundation offers CellCept assistance for insured patients who still face significant out-of-pocket costs. Eligibility requires a specific covered diagnosis, active insurance, and income within program limits. Funding availability varies — programs can open and close based on available resources, so patients should check panfoundation.org for current status.

Strategy: Prescribing Generic Mycophenolate vs. Brand CellCept

For most commercially insured patients, generic mycophenolate mofetil is the lowest-cost option — particularly when the patient uses prescription discount programs like GoodRx or SingleCare. Generic pricing can be as low as $25–$80 for 60 tablets at participating pharmacies, compared to $57.50–$87.50 copays for the same on insurance.

However, for patients on commercial insurance who have been prescribed brand CellCept and enrolled in the Genentech co-pay card program, the brand product may have a lower effective cost ($15/month) than the generic copay. Compare the two options at enrollment and open enrollment each year.

Medicare-Specific Considerations

Medicare Part B covers immunosuppressive drugs for kidney transplant patients enrolled in Part A at the time of transplant, and the Immunosuppressive Drug Benefit under the Consolidated Appropriations Act of 2021 extended this coverage to patients who would otherwise lose Part B drug coverage after 36 months.

Medicare Part D also covers CellCept, but tier placement and copay vary by plan. At open enrollment, help patients compare plans using the Medicare Plan Finder at medicare.gov, specifically checking for their CellCept and full transplant drug list. The Low Income Subsidy (Extra Help) program may further reduce costs for qualifying patients.

Building Cost Management Into Your Practice Workflow

Best practices for integrating cost management into routine transplant care:

Assign a transplant social worker or financial counselor to conduct a cost assessment at transplant discharge and annually thereafter.

Provide patients with a handout listing current savings options at every annual visit.

Screen for medication non-adherence at every visit using a validated tool — the BAASIS scale is commonly used in transplant programs.

When a patient reports a cost barrier, have a clear referral pathway to enrollment in co-pay assistance or PAP programs.

To help patients locate CellCept in stock in addition to managing costs, see medfinder for providers — a real-time pharmacy availability service for all medications.